PURPOSE: To determine the most adequate parameter to measure the consequences of reducing the parotid gland dose. METHODS AND MATERIALS: One hundred eight patients treated with radiotherapy for various malignancies of the head and neck were prospectively evaluated using three methods. Parotid gland function was objectively determined by measuring stimulated parotid flow using Lashley cups and scintigraphy. To assess xerostomia-related quality of life, the head-and-neck cancer module European Organization for Research and Treatment of Cancer QLQ (Quality of Life Questionnaire) H&N35 was used. Measurements took place before radiotherapy and 6 weeks and 12 months after the completion of radiotherapy. Complication was defined for each method using cutoff values. The correlation between these complications and the mean parotid gland dose was investigated to find the best measure for parotid gland function. RESULTS: For both flow and scintigraphy data, the best definition for objective parotid gland toxicity seemed to be reduction of stimulated parotid flow to < or =25% of the preradiotherapy flow. Of all the subjective variables, only the single item dry mouth 6 weeks after radiotherapy was found to be significant. The best correlation with the mean parotid gland dose was found for the stimulated flow measurements. The predictive ability was the highest for the time point 1 year after radiotherapy. Subjective findings did not correlate with the mean parotid dose. CONCLUSIONS: Stimulated flow measurements using Lashley cups, with a complication defined as flow < or =25% of the preradiotherapy output, correlated best with the mean parotid gland dose. When reduction of the mean dose to the parotid gland is intended, the stimulated flow measurement is the best method for evaluating parotid gland function.
PURPOSE: To determine the most adequate parameter to measure the consequences of reducing the parotid gland dose. METHODS AND MATERIALS: One hundred eight patients treated with radiotherapy for various malignancies of the head and neck were prospectively evaluated using three methods. Parotid gland function was objectively determined by measuring stimulated parotid flow using Lashley cups and scintigraphy. To assess xerostomia-related quality of life, the head-and-neck cancer module European Organization for Research and Treatment of Cancer QLQ (Quality of Life Questionnaire) H&N35 was used. Measurements took place before radiotherapy and 6 weeks and 12 months after the completion of radiotherapy. Complication was defined for each method using cutoff values. The correlation between these complications and the mean parotid gland dose was investigated to find the best measure for parotid gland function. RESULTS: For both flow and scintigraphy data, the best definition for objective parotid gland toxicity seemed to be reduction of stimulated parotid flow to < or =25% of the preradiotherapy flow. Of all the subjective variables, only the single item dry mouth 6 weeks after radiotherapy was found to be significant. The best correlation with the mean parotid gland dose was found for the stimulated flow measurements. The predictive ability was the highest for the time point 1 year after radiotherapy. Subjective findings did not correlate with the mean parotid dose. CONCLUSIONS: Stimulated flow measurements using Lashley cups, with a complication defined as flow < or =25% of the preradiotherapy output, correlated best with the mean parotid gland dose. When reduction of the mean dose to the parotid gland is intended, the stimulated flow measurement is the best method for evaluating parotid gland function.
Authors: Vitali Moiseenko; Jonn Wu; Allan Hovan; Ziad Saleh; Aditya Apte; Joseph O Deasy; Stephen Harrow; Carman Rabuka; Adam Muggli; Anna Thompson Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: Tim Dijkema; Cornelis P J Raaijmakers; Randall K Ten Haken; Judith M Roesink; Pètra M Braam; Anette C Houweling; Marinus A Moerland; Avraham Eisbruch; Chris H J Terhaard Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-07 Impact factor: 7.038
Authors: S Tribius; J Sommer; C Prosch; A Bajrovic; A Muenscher; M Blessmann; A Kruell; C Petersen; M Todorovic; P Tennstedt Journal: Strahlenther Onkol Date: 2013-01-27 Impact factor: 3.621
Authors: Piet Dirix; Sandra Nuyts; Vincent Vander Poorten; Pierre Delaere; Walter Van den Bogaert Journal: Support Care Cancer Date: 2007-07-06 Impact factor: 3.603
Authors: C M van Rij; W D Oughlane-Heemsbergen; A H Ackerstaff; E A Lamers; A J M Balm; C R N Rasch Journal: Radiat Oncol Date: 2008-12-09 Impact factor: 3.481